Clinical Trials Logo

Spinocerebellar Ataxia Type 10 clinical trials

View clinical trials related to Spinocerebellar Ataxia Type 10.

Filter by:
  • None
  • Page 1

NCT ID: NCT04495426 Recruiting - Clinical trials for Spinocerebellar Ataxia Type 10

Genetic Mechanism of Conserved Ancestral Haplotype in SCA10

CAHSCA10
Start date: September 15, 2020
Phase:
Study type: Observational

Spinocerebellar ataxia type 10 (SCA10) is a hereditary ataxia whose ancestral mutation occurred in East Asia. The mutation is likely to have migrated during peopling of American continents from East Asia. We found a specific rare DNA variation associated with SCA10. We test whether this variation played a key role in the birth and subsequent spreading of SCA10 mutation.

NCT ID: NCT04301284 Withdrawn - Clinical trials for Spinocerebellar Ataxias

Study of CAD-1883 for Spinocerebellar Ataxia

Synchrony-1
Start date: June 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.

NCT ID: NCT03701399 Active, not recruiting - Clinical trials for Spinocerebellar Ataxias

Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Start date: March 8, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

NCT ID: NCT01793168 Recruiting - Clinical trials for Retinitis Pigmentosa

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS
Start date: July 2010
Phase:
Study type: Observational [Patient Registry]

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org/CoRDS to enroll.